We work to ensure the quality and availability of tuberculosis medicines across the supply chain to limit the spread of multidrug-resistant tuberculosis (MDR-TB). This includes implementing innovative, expedited pathways to register quality-assured TB medicines in Central Asia, where MDR-TB is a persistent threat. It also means strengthening diagnostic and medicine quality control laboratories to better diagnose patients and ensure the quality of TB medicines.
In addition, we work with manufacturers to improve their compliance with global standards and best practices, including developing staff capacity and technical know-how, as well as preparing TB product dossiers for submission and review. Once TB products are approved for market use, we also work with national partners to monitor product safety to help detect any serious potential side effects, or adverse events, that might compromise TB treatment.
Spotlight on Central Asia
USP’s technical assistance to strengthen laboratory networks, improve pharmacovigilance, and support manufacturers and regulators to register medical products, helps improve access to quality-assured TB medicines in Central Asia and worldwide. Through funding from the U.S. Agency for International Development (USAID), the Promoting the Quality of Medicines Plus (PQM+) program, along with predecessor programs, have helped achieve WHO prequalification or stringent regulatory approvals (SRAs) of 27 TB products, including 11 finished products and 16 active pharmaceutical ingredients across the globe.
Building a resilient supply chain for TB
Preventing, treating, and curing patients with MDR-TB is a major public health challenge in the Kyrgyz Republic and worldwide.
Project spotlight: Kyrgyz Republic
Strengthening early detection and supply chain management of TB helps ensure quality medicines for patients.